Versus chemotherapy, enfortumab vedotin (Padcev) produced superior outcomes following platinum-based chemotherapy and PD-1/L1 inhibition in patients with advanced urothelial carcinoma, according to results of the phase 3 EV-301 clinical trial (NCT03474107) that were presented at the 2021 Genitourinary (GU) Cancers Symposium.1,2
These findings, which were simultaneously published in the New England Journal of Medicine, showed that efficacy benefits were observed in terms of progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for enfortumab vedotin.
“Enfortumab vedotin is the first drug beyond chemotherapy and immunotherapy to show a significant survival advantage in previously treated advanced urothelial cancer,” said Thomas Powles, MBBS, MRCP, MD, in a presentation during the GU Cancers Symposium. “This is a big step in the right direction…
